

REFERENCES

- Armstrong, T.S. *et al.* (2016) ‘Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with MALIGNANT GLIOMAS: Panel 1 report’, *Neuro-Oncology*, 18(suppl 2), pp. ii1–ii12. doi:10.1093/neuonc/nov267.
- Avellaneda Matteo, D. *et al.* (2017) ‘Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency’, *Journal of Biological Chemistry*, 292(19), pp. 7971–7983. doi:10.1074/jbc.m117.776179.
- Berger, A. (2002a) ‘How does it work?: Magnetic resonance imaging’, *BMJ*, 324(7328), pp. 35–35. doi:10.1136/bmj.324.7328.35.
- Biswas, A. *et al.* (2022) ‘Features of visually accesable Rembrandt Images: Interrater Reliability in pediatric brain tumors’, *American Journal of Neuroradiology*, 43(2), pp. 304–308. doi:10.3174/ajnr.a7399.
- Butowski, N.A. (2015) ‘Epidemiology and diagnosis of brain tumors’, *CONTINUUM: Lifelong Learning in Neurology*, 21, pp. 301–313. doi:10.1212/01.con.0000464171.50638.fa.
- Carozza, S.E. (2000) ‘Occupation and adult gliomas’, *American Journal of Epidemiology*, 152(9), pp. 838–846. doi:10.1093/aje/152.9.838.
- Dahlrot, R.H. *et al.* (2021) ‘Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells’, *Scientific Reports*, 11(1). doi:10.1038/s41598-021-95958-9.
- degrees of glioma and IDH status prediction: A possible machine learning application?’, *Journal of Imaging*, 9(4), p. 75. doi:10.3390/jimaging9040075.
- Ellingson, B.M. (2014) ‘Radiogenomics and imaging phenotypes in glioblastoma: Novel observations and correlation with molecular characteristics’, *Current Neurology and Neuroscience Reports*, 15(1). doi:10.1007/s11910-014-0506-0.
- Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., *et al.* (2000). Inactivation of the DNA-Repair Gene MGMT

and the Clinical Response of Gliomas to Alkylating Agents. *New England Journal of Medicine* 343: 1350–1354.

Gaillard, F. (2016) ‘Vasari MRI feature set’, Radiopaedia.org [Preprint]. doi:10.53347/rid-45816. Gemini, L. *et al.* (2023) ‘Vasari scoring system in discerning between different

Gemini, L. *et al.* (2023) ‘Vasari scoring system in discerning between different degrees of glioma and IDH status prediction: A possible machine learning application?’, *Journal of Imaging*, 9(4), p. 75. doi:10.3390/jimaging9040075.

Gladson, C.L., Prayson, R.A. and Liu, W.M. (2010) ‘The pathobiology of glioma tumors’, *Annual Review of Pathology: Mechanisms of Disease*, 5(1), pp. 33–50. doi:10.1146/annurev-pathol-121808-102109.

Grover, V.P.B. *et al.* (2015) ‘Magnetic Resonance Imaging: Principles and techniques: Lessons for clinicians’, *Journal of Clinical and Experimental Hepatology*, 5(3), pp. 246–255. doi:10.1016/j.jceh.2015.08.001.

Han, S. *et al.* (2020) ‘IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets’, *British Journal of Cancer*, 122(11), pp. 1580–1589. doi:10.1038/s41416-020-0814-x.

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., Tribolet, N. de, Weller, M., *et al.* (2005). MGMT Gene Silencing and Benefits of Temozolomide in Glioblastoma. *New England Journal of Medicine* 352 : 997–1003.

heresia, E. *et al.* (2020) ‘Association between Ki-67 labeling index and histopathological grading of glioma in Indonesian population’, *Asian Pacific Journal of Cancer Prevention*, 21(4), pp. 1063–1068. doi:10.31557/apjcp.2020.21.4.1063.

Holick, C.N. *et al.* (2007) ‘Prospective study of cigarette smoking and adult glioma: Dosage, duration, and latency’, *Neuro-Oncology*, 9(3), pp. 326–334. doi:10.1215/15228517-2007-005.

IJzerman-Korevaar, M. *et al.* (2018) ‘Prevalence of symptoms in glioma patients throughout the disease trajectory: A systematic review’, *Journal of Neuro-Oncology*, 140(3), pp. 485–496. doi:10.1007/s11060-018-03015-9.

- Jia, Z., Li, X., Yan, Y., Shen, X., Wang, J., Yang, H., et al. (2022). Exploring the relationship between age and prognosis in glioma: rethinking current age stratification. *BMC Neurology* 22 : 350.
- Kortz, M.W. (2023) *Insular cortex, StatPearls [Internet]*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK570606/#:~:text=The%20insula%20is%20important%20for,and%20auditory%20and%20vestibular%20functioning>. (Accessed: 24 June 2024).
- LI, L.T. *et al.* (2014) ‘KI67 is a promising molecular target in the diagnosis of cancer (review)’, *Molecular Medicine Reports*, 11(3), pp. 1566–1572. doi:10.3892/mmr.2014.2914.
- Louis, D. N., Perry, A., Reifenberger, G., Deimling, A. von, Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica* 131 : 803–820.
- Louis, D.N. et al. (2021) ‘The 2021 who classification of tumors of the central nervous system: A summary’, *Neuro-Oncology*, 23(8), pp. 1231–1251. doi:10.1093/neuonc/noab106.
- Nicholson, J.G., & Fine, H.A. (2021). Diffuse Glioma Heterogeneity and Its Therapeutic Implications. *Cancer Discov* 11 : 575–590.
- Omuro, A. (2013) ‘Glioblastoma and other malignant gliomas’, *JAMA*, 310(17), p. 1842. doi:10.1001/jama.2013.280319.
- Omuro, A. (2013) ‘Glioblastoma and other malignant gliomas’, *JAMA*, 310(17), p. 1842. doi:10.1001/jama.2013.280319.
- Ostrom, Q.T. et al. (2014) ‘Epidemiology of gliomas’, *Cancer Treatment and Research*, pp. 1–14. doi:10.1007/978-3-319-12048-5_1.
- Park, C.J., Han, K., Kim, H., Ahn, S.S., Choi, D., Park, Y.W., et al. (2021). MRI Features Can Predict Glioblastoma Molecular Features in Isocitrate Dehydrogenase Wild-Type Low-Grade Gliomas. *American Journal of Neuroradiology* 42 : 448–456.
- Park, Y.W. *et al.* (2017) ‘Prediction of *idh1*-mutation and 1P/19Q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas’, *American Journal of Neuroradiology*, 39(1), pp. 37–42. doi:10.3174/ajnr.a5421.

- Pellerino, A., Caccese, M., Padovan, M. et al. Epidemiology, risk factors, and prognostic factors of gliomas. *Clin Transl Imaging* 10, 467–475 (2022).
- Saclic-Bilmez, B., Firat, Z., Topcuoglu, O. M., Yaltirik, K., Ture, U., & Ozturk-Isik, E. (2023). Identifying overall survival in 98 glioblastomas using VASARI features at 3T. *Clin Imaging* 93 : 86–92.
- Sagberg, L. M., Iversen, D. H., Fyllingen, E. H., Jakola, A. S., Reinertsen, I., & Solheim, O. (2019). Brain Atlas for assessing the impact of tumor location on perioperative quality of life in patients with high-grade glioma: A prospective population-based cohort study. *NeuroImage: Clinical*, 21, 101658. <https://doi.org/10.1016/j.nicl.2019.101658>
- Sahu, A. *et al.* (2022) ‘Multiparametric magnetic resonance imaging correlates of isocitrate dehydrogenase mutation in who high-grade astrocytomas’, *Journal of Personalized Medicine*, 13(1), p. 72. doi:10.3390/jpm13010072.
- Schwartzbaum, J.A. et al. (2006) ‘Epidemiology and molecular pathology of glioma’, *Nature Clinical Practice Neurology*, 2(9), pp. 494–503. doi:10.1038/ncpneuro0289.
- Singh, G. et al. (2021) ‘Radiomics and radiogenomics in gliomas: A contemporary update’, *British Journal of Cancer*, 125(5), pp. 641–657. doi:10.1038/s41416-021-01387-w.
- Singh, G., Manjila, S., Sakla, N., True, A., Wardeh, A.H., Beig, N., *et al.* (2021). Radiomics and radiogenomics in gliomas: a contemporary update. *British Journal of Cancer*.
- Smits, M., & Bent, M. J. V. D. (2017). Imaging correlates of adult glioma genotypes. *Radiology* 284 : 316–331.
- Thomas, L., Di Stefano, A.L. and Ducray, F. (2013) ‘Predictive biomarkers in adult gliomas’, *Current Opinion in Oncology*, 25(6), pp. 689–694. doi:10.1097/cco.0000000000000002.
- Weller, M. *et al.* (2009) ‘MGMT promoter methylation in malignant gliomas: Ready for personalized medicine?’, *Nature Reviews Neurology*, 6(1), pp. 39–51. doi:10.1038/nrneuro.2009.197.
- Weller, M. *et al.* (2015) ‘Glioma’, *Nature Reviews Disease Primers*, 1(1). doi:10.1038/nrdp.2015.17.

Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., & Reifenberger, G. (2015, July 16). Glioma. *Nature News*. <https://www.nature.com/articles/nrdp201517>

Yang, M. *et al.* (2017) 'Mobile phone use and glioma risk: A systematic review and meta-analysis', *PLOS ONE*, 12(5). doi:10.1371/journal.pone.0175136.

Zhang, L., He, L., Lugano, R., Roodakker, K., Bergqvist, M., Smits, A., et al. (2018). IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. *Neuro-Oncology* 20 : 1505–1516.

Zhang, W. *et al.* (2022) 'Dietary factors and risk of glioma in adults: A systematic review and dose-response meta-analysis of observational studies', *Frontiers in Nutrition*, 9. doi:10.3389/fnut.2022.834258.

Zhou, H. *et al.* (2017) 'MRI features predict survival and molecular markers in diffuse lower-grade gliomas', *Neuro-Oncology*, 19(6), pp. 862–870. doi:10.1093/neuonc/now256.